Related Experiment Videos
Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy
Archana Rao1, Susana D'Amico, Ashok Balasubramanyam
1Division of Endocrinology, Baylor College of Medicine, and Endocrine Service, Ben Taub General Hospital, Houston, Texas, USA.
The American Journal of the Medical Sciences
|June 18, 2004
Summary
Fenofibrate effectively treats high triglycerides in patients with HIV lipodystrophy syndrome. This study shows significant triglyceride reduction with good tolerability, offering a valuable treatment option.
Area of Science:
- Endocrinology
- Infectious Diseases
- Pharmacology
Background:
- Highly active antiretroviral therapy (HAART) for HIV can cause lipodystrophy syndrome (HLS).
- HLS is frequently associated with dyslipidemia, particularly hypertriglyceridemia.
- Managing hypertriglyceridemia in HLS is crucial for reducing cardiovascular risk.
Purpose of the Study:
- To evaluate the efficacy and tolerability of fenofibrate.
- To treat hypertriglyceridemia in adult patients diagnosed with HLS.
- To assess lipid profile changes after fenofibrate intervention.
Main Methods:
- 55 adult patients with HLS and hypertriglyceridemia were enrolled.
- Patients received escalating doses of fenofibrate (54-162 mg/day) for 6 months.
- Fasting lipid concentrations were measured at baseline and after 6 months.
Main Results:
- Fenofibrate significantly reduced triglyceride levels (P < 0.05).
- Mean triglyceride levels decreased from 886 +/- 172 mg/dL to 552 +/- 104 mg/dL.
- Total cholesterol and HDL cholesterol levels showed no significant changes.
- Fenofibrate was well-tolerated, with no study dropouts.
Conclusions:
- Fenofibrate is an effective treatment for hypertriglyceridemia in HLS patients.
- The medication demonstrated good tolerability in the study population.
- Fenofibrate represents a viable therapeutic option for managing dyslipidemia in HLS.